BAM
ACET icon

Brave Asset Management’s Adicet Bio ACET Stock Holding History

Brave Asset Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-208
Closed -$50K – 123
2020
Q2 		$50K Hold
208
– – 0.03% 109
2020
Q1 		$24K Hold
208
– – 0.02% 120
2019
Q4 		$35K Buy
208
+71
+52% +$35.9K 0.02% 155
2019
Q3 		$135K Buy
+137
New +$153K 0.08% 136

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Brave Asset Management's ACET Position: Q3 2020 in Review

Brave Asset Management sold out of Adicet Bio (ACET) in Q3 2020, closing a stake of 208 shares — an estimated $50K sold.

Brave Asset Management first reported a position in ACET in Q3 2019 and held it in 4 quarters. The position peaked at $135K in Q3 2019. 32 funds tracked by Wall St. Rank hold ACET as of Q3 2020.

  • Brave Asset Management reported no remaining Adicet Bio position as of Q3 2020 after selling out during the quarter.
  • Brave Asset Management sold 208 Adicet Bio shares in Q3 2020, an estimated $50K.
  • Brave Asset Management first reported a position in Adicet Bio in Q3 2019 and held it in 4 quarters.
  • Brave Asset Management's Adicet Bio position peaked at $135K in Q3 2019.
  • 32 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2020.

Based on Brave Asset Management's 13F filing for Q3 2020, filed 19 Oct 2020.